DZD 1516
Alternative Names: DZD-1516Latest Information Update: 11 Dec 2023
At a glance
- Originator Dizal Pharmaceutical
- Class Antineoplastics
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 positive breast cancer
Most Recent Events
- 11 Dec 2023 Phase I development is ongoing in USA and China (Dizal Pharmaceutical pipeline, December 2023)
- 05 Sep 2022 Efficacy, Adverse events and Pharmacokinetics data from a phase I trial in Breast cancer presented at the European Society for Medical Oncology Annual Meeting (ESMO-2022)
- 03 Jun 2022 Adverse events and pharmacokinetics data from a phase I trial in Breast cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)